Saroglitazar magnesium
Based on 10 publication(s) in Google Scholar
Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
For research use only. We do not sell to patients.
- Purity: 98.02%
- CAS No.: 1639792-20-3
- Formula: C50H56MgN2O8S2
- Molecular Weight:901.42
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Metabolism/Protease Compound Library
HY-L012
-
Clinical Compound Library
HY-L026
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Anti-diabetic Compound Library
HY-L040
-
Anti-Obesity Compound Library
HY-L087
-
Transcription Factor-Targeted Library
HY-L090
-
Lipid Metabolism Compound Library
HY-L091
-
Rare Diseases Drug Library
HY-L102
-
Antidepressant Compound Library
HY-L108
-
Nuclear Receptor Compound Library
HY-L126
-
Osteogenesis Compound Library
HY-L131
-
Cancer Stem Cells Compound Library
HY-L135
-
Mitochondrial Protection Compound Library
HY-L144
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Activators Library
HY-L159
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Saroglitazar magnesium
More- Acta Pharm Sin B. 2025 Dec;15(12):6382-6398. [Abstract]
- Sci Adv. 2025 Sep 26;11(39):eads3731. [Abstract]
- Cell Biol Toxicol. 2021 Apr;37(2):293-311. [Abstract]
- Ann Med. 2025 Dec;57(1):2497112. [Abstract]
- iScience. 2025 Apr 3;28(5):112344. [Abstract]
- BMC Complement Med Ther. 2021 Apr 10;21(1):118. [Abstract]
- Medicina (Kaunas). 2025 Jun 26;61(7):1157. [Abstract]
- SSRN. 2024 May 30.
- Patent. US20210275504A1.
- Patent. US20190388398A1.
Customer Validation & Images
-
Histological Imaging/Staining
-
IF
-
WB
-
RT-PCR
-
ELISA
Biological Activity
|
PPARα 0.65 pM (EC50, HepG2 cell) |
PPARγ 3 nM (EC50, HepG2 cell) |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1639792-20-3
-
Appearance Solid
-
Molecular Weight 901.42
-
Formula C50H56MgN2O8S2
-
Color Off-white to light yellow
-
SMILES
CCO([Mg+2]1(O(CC)[C@H](C([O-]1)=O)CC2=CC=C(OCCN3C(C)=CC=C3C4=CC=C(SC)C=C4)C=C2)[O-]C5=O)[C@H]5CC6=CC=C(OCCN7C(C)=CC=C7C8=CC=C(SC)C=C8)C=C6
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Acta Pharm Sin B
2025 Dec;15(12):6382-6398. PMID: 41477334 -
Sci Adv
Nanomedicine targeting PPAR in adipose tissue macrophages improves lipid metabolism and obesity-induced metabolic dysfunction. [Abstract]2025 Sep 26;11(39):eads3731. PMID: 41004576 -
Cell Biol Toxicol
2021 Apr;37(2):293-311. PMID: 32613381 -
Ann Med
PPAR-mediated reduction of lipid accumulation in hepatocytes involves the autophagy-lysosome-mitochondrion axis. [Abstract]2025 Dec;57(1):2497112. PMID: 40289698 -
iScience
2025 Apr 3;28(5):112344. PMID: 40276762 -
BMC Complement Med Ther
Effect of Shuangdan Mingmu capsule, a Chinese herbal formula, on oxidative stress-induced apoptosis of pericytes through PARP/GAPDH pathway. [Abstract]2021 Apr 10;21(1):118. PMID: 33838689 -
Medicina (Kaunas)
Saroglitazar Ameliorates Pulmonary Fibrosis Progression in Mice by Suppressing NF-κB Activation and Attenuating Macrophage M1 Polarization. [Abstract]2025 Jun 26;61(7):1157. PMID: 40731787
Saroglitazar magnesium purchased from MedChemExpress. Usage Cited in: Medicina (Kaunas). 2025 Jun 26;61(7):1157. [Abstract]
HE staining of lung tissue in control, BLM, and BLM mice treated with SGZ (10 mg/kg, p.o.).
Saroglitazar magnesium purchased from MedChemExpress. Usage Cited in: Medicina (Kaunas). 2025 Jun 26;61(7):1157. [Abstract]
IF staining of collagen 1 of lung tissue in control, BLM, and BLM mice treated with SGZ (10 mg/kg, p.o.).
Saroglitazar magnesium purchased from MedChemExpress. Usage Cited in: Medicina (Kaunas). 2025 Jun 26;61(7):1157. [Abstract]
Western blot analysis of lung tissue of control, BLM, and BLM mice treated with SGZ (10 mg/kg, p.o.).
Saroglitazar magnesium purchased from MedChemExpress. Usage Cited in: Medicina (Kaunas). 2025 Jun 26;61(7):1157. [Abstract]
PCR analysis of IL-1β, IL-6, and TNF-α in RAW264.7 treated with BLM and SGZ (10 μM).
Saroglitazar magnesium purchased from MedChemExpress. Usage Cited in: Medicina (Kaunas). 2025 Jun 26;61(7):1157. [Abstract]
ELISA analysis of IL-1β, IL-6, and TNF-α of RAW264.7 treated with BLM and SGZ (10 μM).
-
-
-
Solvent & Solubility
DMSO : 125 mg/mL (138.67 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.75 mg/mL (3.05 mM); Clear solution
This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.75 mg/mL (3.05 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.75 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Rats: Rats randomize based on body weights and are divided into three equal groups and receives the daily administration of vehicle (50% w/v honey for marmoset and 0.1% carboxymethylcellulose for Wistar rats) or Saroglitazar (1.5 and 15 mg/kg per day) for 90 days by oral gavage[1].
Mice: Male C57BL/6J-db/db mice are bled on day 0 to determine pretreatment serum glucose and TG. During next 12 days, each animal is dosed (by oral gavage) with vehicle (0.5% sodium carboxymethyl cellulose) or Saroglitazar (0.01, 0.03, 0.1, 0.3,1, and 3 mg/kg per day) or U 72107 (60 mg/kg per day) and on day 12 of the treatment, blood samples are collected (1 h after dosing) from orbital sinus under light ether anesthesia. The serum is isolated and analyzed for glucose, TG, and free fatty acid (FFA)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.1094 mL | 5.5468 mL | 11.0936 mL | 27.7340 mL |
| 5 mM | 0.2219 mL | 1.1094 mL | 2.2187 mL | 5.5468 mL | |
| 10 mM | 0.1109 mL | 0.5547 mL | 1.1094 mL | 2.7734 mL | |
| 15 mM | 0.0740 mL | 0.3698 mL | 0.7396 mL | 1.8489 mL | |
| 20 mM | 0.0555 mL | 0.2773 mL | 0.5547 mL | 1.3867 mL | |
| 25 mM | 0.0444 mL | 0.2219 mL | 0.4437 mL | 1.1094 mL | |
| 30 mM | 0.0370 mL | 0.1849 mL | 0.3698 mL | 0.9245 mL | |
| 40 mM | 0.0277 mL | 0.1387 mL | 0.2773 mL | 0.6934 mL | |
| 50 mM | 0.0222 mL | 0.1109 mL | 0.2219 mL | 0.5547 mL | |
| 60 mM | 0.0185 mL | 0.0924 mL | 0.1849 mL | 0.4622 mL | |
| 80 mM | 0.0139 mL | 0.0693 mL | 0.1387 mL | 0.3467 mL | |
| 100 mM | 0.0111 mL | 0.0555 mL | 0.1109 mL | 0.2773 mL |
Powered by Bioz